10% of eligible T2D patients get new but pricey drugs PharmTwitter EndoTwitter
"Clinical studies have shown that both GLP-1 [glucagon-like peptide-1] receptor agonists and SGLT2 [sodium-glucose cotransporter 2] inhibitors yield additional clinical benefits compared with older treatments in reducing body weight and progression of cardiovascular disease and chronic kidney disease," write Shichao Tang, PhD, from the US Centers for Disease Control and Prevention , Atlanta, Georgia, and colleagues.
Excluding those who likely had type 1 diabetes and those with incomplete data left 1330 survey participants, including 1133 who fit criteria for the treatment of type 2 diabetes with an agent from one of the two studied classes, asby a panel representing the American Diabetes Association and the European Association for the Study of Diabetes.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
A Texas Bill Would Offer Huge Tax Breaks to Straight Couples Who Have 10—10!—KidsEven if a couple is currently married, the Texas tax break would not apply if either person had previously been divorced.
Les mer »
The only way to reverse Type 2 diabetes is to get control of itThe three most important areas of controlling diabetes are diet, exercise and weight.
Les mer »
S2 Episode 3: Advances in Chronic Kidney Disease Care in Type 2 DiabetesJoin Dr Carol Wysham and Dr Katherine Tuttle as they discuss advances in chronic kidney disease prevention and management in patients living with type 2 diabetes.
Les mer »
Drugmaker to slash prices for some insulin medicationPeople with Type 1 diabetes must take insulin every day to survive.
Les mer »
10 Dishes Every Beginner Cook Should LearnWhat's the best dish for a beginner cook to try? We asked star chefs from all over the country for their recommendations. Here's what they had to say.
Les mer »
Times Sports earns third consecutive APSE grand slam, nine top-10 honorsThe Times has earned the Associated Press Sports Editors' most prestigious honor, the grand slam, for the third consecutive year.
Les mer »